Pacira Pharmaceuticals
As of the edition of 20 October 2026, Pacira Pharmaceuticals runs 7 drugs, 4 of them marketed; it is on route A at 1 target and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Pacira Pharmaceuticals was renamed in 2019.
The records place 2 company names in this family.
- Pacira Pharmaceuticals, Inc: renamed in 2019
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Went quiet | 1 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cytarabine | none listed | 0 |
| Bupivacaine | none listed | 1 |
| Morphine | none listed | 2 |
| Triamcinolone acetonide | none listed | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 1 target.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Pacira Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Bones, joints and muscles: 4 trials led